Cellular Biomedicine Group (CBMG) Tops Q1 EPS by 1c

Cellular Biomedicine Group (NASDAQ: CBMG) reported Q1 EPS of ($0.39), $0.01 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $603.4 thousand, versus $61.1 thousand reported last year.

For earnings history and earnings-related data on Cellular Biomedicine Group (CBMG) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Raymond James on Malibu Boats (MBUU): 'continued soft retail environment'
• Herbalife reaffirms Q3 and full-year 2026 financial guidance